Fiche publication
Date publication
juillet 2025
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Amrane K, Cabarrou B, Justeau G, Schneider S, Quantin X, Falchero L, Bigot F, Ferrari V, Guisier F, Girard N, Lena H, Dansin E, Madroszyk A, Bizieux A, Debieuvre D, Perol M, Simoneau Y, Bosquet L, Descourt R, Chouaïd C
Lien Pubmed
Résumé
Among the aggressive non-small-cell lung carcinoma subtypes, pulmonary sarcomatoid carcinoma (PSC) is a rare and poorly understood tumor. This study was undertaken to evaluate the efficacy [progression-free survival (PFS) and overall survival (OS)] of first-line immune checkpoint inhibitor (ICI) with or/without (±) chemotherapy (ChT) versus ChT alone against advanced PSCs (APSCs).
Mots clés
NSCLC, PD-L1, chemotherapy, immunotherapy, pulmonary sarcomatoid carcinoma
Référence
ESMO Open. 2025 07 23;10(8):105343
